| 钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病保护机制的研究进展 |
| |
| 引用本文： | 郭诗哲.钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病保护机制的研究进展[J].复旦学报(医学版),2018,45(2):250. |
| |
| 作者姓名： | 郭诗哲 |
| |
| 作者单位： | 复旦大学附属华山医院内分泌科-复旦大学内分泌糖尿病研究所 上海 200040 |
| |
| 基金项目： | 国家自然科学基金面上项目(81370938);上海市卫计委优秀青年人才计划(XYQ2011002) |
| |
| 摘 要： | 糖尿病肾病(diabetic kidney disease, DKD)是导致终末期肾病(end-stage renal disease, ESRD)的主要原因,其防治是目前临床和基础研究的热点与重点。钠-葡萄糖协同转运蛋白2(sodium-glucose cotransporter 2, SGLT2)抑制剂是一种新型降糖药物,除了降糖作用以外,还有肾脏保护作用,其机制可能包括降低血糖、改善肾脏血流动力学稳态、减轻氧化应激、减少肾小管间质损伤、抑制肾脏炎症及纤维化和降低尿酸水平等。本文就SGLT2抑制剂对DKD保护机制的研究进展作一综述。
|
| 关 键 词： | 钠-葡萄糖协同转运蛋白2 抑制剂 糖尿病肾病 |
| 收稿时间： | 2016-09-08 |
Advance in the mechanism of protective effects of SGLT2 inhibitor on diabetic kidney disease |
| |
| GUO Shi-zhe,ZHANG Zhao-yun.Advance in the mechanism of protective effects of SGLT2 inhibitor on diabetic kidney disease[J].Fudan University Journal of Medical Sciences,2018,45(2):250. |
| |
| Authors: | GUO Shi-zhe ZHANG Zhao-yun |
| |
| Institution: | Department of Endocrinology and Metabolism, Huashan Hospital-Institute of Endocrinology and Diabetology, Fudan University, Shanghai 200040, China |
| |
| Abstract: | Diabetic kidney disease (DKD) is one of the major causes for end-stage renal disease (ESRD), which has been the focus of both clinical and basic research. Sodium-glucose cotransport 2 (SGLT2) inhibitors are a new type of anti-diabetic drugs, which also showed reno-protective effects. The potential mechanisms include decreasing plasma glucose, improving glomerular hyperfiltration, reducing oxidative stress, tubulointerstitial injury, suppressing inflammation and fibrosis, decreasing the level of uric acid, and etc. This review focuses on the advance in the mechanism of protective effects of SGLT2 inhibitor on DKD. |
| |
| Keywords: | sodium-glucose cotransporter 2 inhibitor diabetic kidney disease |
|
| 点击此处可从《复旦学报(医学版)》浏览原始摘要信息 |
| 点击此处可从《复旦学报(医学版)》下载免费的PDF全文 |
